USD 350.53 million
Report ID: SQMIG35H2058 | Region: Global | Published Date: February, 2024 | Pages: 157 | Tables: 99 | Figures: 67
Biopharmaceuticals Market was valued around USD 350.53 million in 2021 and is expected to rise from USD 377.87 million in 2022 to reach USD 689.12 million by the end of 2030, by recording a CAGR of 7.80% during the forecast period (2023-2030).
A biopharmaceutical is a business that provides services to other biopharmaceutical companies on a contract basis, including packaging and drug manufacturing. This permits major biopharmaceutical associations to rethink their assembling activity, hence empowering them to zero in on drug revelation and medication promoting. Due to a lack of in-house production capacity, a number of small biotechnology companies outsource fill and finish manufacturing, which helps reduce capital expenditures. Biopharmaceuticals are drugs that are used for medical purposes and are made by using biotechnology to extract proteins and nucleic acids directly from the biological source. The majority of biopharmaceuticals are pharmaceuticals derived from living things. Genetically modified plants and animals are referred to as transgenic organisms. This process is used to produce biopharmaceuticals, but it is a highly contentious approach that is still in the trial phase. One of the first substances to be approved for therapeutic purposes was recombinant human insulin; currently, nearly 300 biopharmaceutical products have been approved and are available for purchase. The growth of this market is being driven by a few key factors, including an expanding geriatric population, rising levels of awareness, and rising costs associated with healthcare. In addition, this market is anticipated to benefit from ongoing R&D and approval for newer biopharmaceutical products. However, one of the industry's biggest obstacles is the high cost of these drugs, which must be significantly reduced to make the business viable.
US Biopharmaceuticals Market is poised to grow at a sustainable CAGR for the next forecast year.
Global Market Size
USD 350.53 million
To get more reports on the above market click here to Buy The Report
The global biopharmaceuticals market is segmented on the basis of product type, application, end use, and region. With respect to segmentation by product type, the market is segmented into the Monoclonal Antibodies, Gene Therapies, Thrombolytics and Anticoagulants, and Recombinant Protein. Based on classification by application, the market is categorized into Oncology, Inflammatory Diseases, Cardiology, Neurology, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders, and Others. With respect to categorization by end use, the market is grouped into Health and Care, Biopharma Companies, Diagnostic Labs, Clinical Research Institute, Clinical Research Organizations (CROs), and Others. Region wise, the market is widespread into North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa.
Biopharmaceuticals Market Analysis by Product type
Based on the product type, In 2022, the Recombinant Protein Segment commanded the largest share of the market. This growth is due to the use of microorganisms in gene therapy and the production of human proteins using recombinant DNA technology. Since 1985, linear growth has been stimulated with recombinant growth hormone.IGF-1 (insulin-like growth factor 1) secretion is the primary mechanism by which rGH functions.In recent years, rhGH has helped children with growth retardation who are GH deficient (GHD).The use of recombinant DNA technology to treat serious illnesses like these is further propelling the biopharmaceutical market's expansion. In addition, it is anticipated that the Monoclonal Antibodies segment will expand at the fastest CAGR of 8.8% between the years 2023 and 2030 due to the widespread use of monoclonal antibodies in oncology to treat a variety of cancers and the key benefits of monoclonal antibodies in the diagnosis and treatment of "cancer," "myocardial infarctions," and development therapy for "neoplastic and hematopoietic disease," as well as a plethora.
Biopharmaceuticals Market Analysis by End use
On the basis of end use, The Health and Care, Biopharma Companies, Diagnostic Labs, Clinical Research Institute, Clinical Research Organizations (CROs), and Others. In 2022, the biopharma companies segment held the largest share of the market. This growth is due to the significant advancements in new medicine and its application to the treatment of complex diseases. This market is also expanding as a result of the recent progress in molecular medicine research and development made by numerous prominent market players and government agencies. In addition, it is anticipated that the Clinical Research Organizations segment will expand at the fastest CAGR of 9.1% between the years 2023 and 2030 as a result of the expansion of research into the development of novel molecular drugs through the use of molecular biology and the assistance that clinical research organizations provide to patients in the form of individualized treatment in order to diagnose and treat complex diseases.
To get detailed analysis on other segments, Request For Sample Report
North America Expected to Dominate the Market, The biopharmaceuticals market in North America is being driven primarily by the rising incidence of chronic diseases in the United States and rising investments in R&D.In the field of life sciences, the United States has been acknowledged as the global innovation capital.In the early stages of biopharmaceutical companies, it participates in global capital investments. The North American biopharmaceuticals market is anticipated to expand as a result of the increase in COVID-19-related clinical trials.Nearly 1,750 clinical trials for the development of vaccines and drugs for the treatment of COVID-19 were in progress as of January 2021, according to the Pharmaceutical Research and Manufacturers of America. 420 of these clinical trials were based in the United States. Globocan estimates that there will be 2,281,658 new cases of cancer in the United States in 2020.Additionally, 612,390 deaths were recorded. The studied market is driven by the demand for effective therapeutics and the high incidence of cancer.
In Walk 2020, Thermo Fisher Logical Inc. contributed almost USD 475 million to grow its biologics, cell and quality treatment, and medication item improvement offices and increment its worldwide business abilities. In a similar vein, Eli Lilly and Company agreed to acquire Dermira, a biopharmaceutical company, in January 2020.The addition of Dermira's lebrikizumab, an IL-13 antibody intended for the treatment of moderate-to-severe atopic dermatitis, to the company's biopharmaceutical portfolio aided this acquisition.
As a result, the studied market is anticipated to expand significantly in North America over the forecast period due to the aforementioned factors.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Biopharmaceuticals Market Drivers
Increase in Chronic Disease Patient Pool to Propel Growth
Biopharmaceuticals Market Restraints
On account of the low incomes and the high burden of healthcare costs, people in developing nations are unable to afford biomedicines and therapies. This may prevent the market from expanding significantly in the forecast period. In 2020, as per Joined Country Improvement Program, 1.3 billion individuals which is 22% of the all-out populace are living in neediness. They are unable to acquire better healthcare facilities because of their poor financial situation. Due to a lack of high-quality healthcare infrastructure, half of the world's population is unable to access essential medical facilities, according to the World Health Organization(WHO).The biopharmaceuticals market is experiencing difficulties as a result of these issues.
Speak to one of our ABIRAW analyst for your custom requirements before the purchase of this report
There are numerous major players in the highly competitive biopharmaceuticals market. Some mid-size and small businesses are expanding their geographical reach as a result of technological advancements and product innovations. Players such as Pfizer Inc., and AstraZeneca PLC both have a large share of the biopharmaceutical market and are involved in a variety of strategic alliances, including acquisitions and partnerships, to expand their product lines.
Biopharmaceuticals Market Top Players Company Profile
Biopharmaceuticals Market Recent Developments
The primary factor contributing to the rapid expansion of the biopharmaceuticals market is the successful therapeutic application of monoclonal antibodies and antibody derivatives. Cancer, rheumatoid arthritis, multiple sclerosis, and cardiovascular diseases are some of the conditions for which monoclonal antibodies can be used as therapeutic agents. Healthcare systems have been experiencing significant strain as a result of the COVID-19 outbreak. Researchers from all over the world are constantly trying to deal with this growing burden. As a result, demand for COVID-19-specific monoclonal antibodies is likely to soar. For instance, the Drug Controller General of India (DCGI) granted approval in July 2020 for the emergency treatment of cytokine release syndrome in patients with acute respiratory distress syndrome who are also infected with COVID-19 with an anti-CD6 IgG1 monoclonal antibody manufactured by Biocon Ltd. (India). In addition, the segment is anticipated to be driven by increasing FDA approvals and new product launches for various indications. For instance, MacroGenics' MARGENZATM was approved by the US Food and Drug Administration (FDA) in December 2020 for the treatment of pretreated metastatic HER2-positive breast cancer. For the treatment of relapsed or refractory multiple myeloma, the FDA approved GlaxoSmithKline's belantamab mafodotin-blmf (BLENREP) in August 2020. As a result, it is anticipated that the biopharmaceuticals market will expand significantly over the forecast period as a result of the aforementioned factors.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyzes the Data collected using Primary Exploratory Research backed by robust Secondary Desk research.
According to our biopharmaceuticals market analysis, the primary factor contributing to the rapid expansion of this market is the successful therapeutic application of monoclonal antibodies and antibody derivatives. The increase in prevalence of cardiac issues as a result of lifestyle changes and irregular eating and sleeping habits are likely to increase the patient pool for different chronic diseases. This is projected to aid in expansion of the global biopharmaceuticals market in the long run. Regionwise, North America is expected to dominate the market in the coming years. The recombinant protein segment held the largest share of the market.
|Market size value in 2021
|USD 350.53 million
|Market size value in the
|USD 377.87 million
|Forecast Unit (Value)
|North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)
Free report customization with purchase. Customization includes:-
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Parent Market Analysis
KEY MARKET INSIGHTS
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
For the Global Biopharmaceuticals Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Global Biopharmaceuticals Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Global Biopharmaceuticals Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Global Biopharmaceuticals Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "
- Mr. Ali Zali, Commercial Director, ICIIC Iran.